Adverse effects of drugs and medicaments, initial encounter

Code Families in This Category

• T43 Poisoning by, adverse effect of and underdosing of psychotropic drugs, not elsewhere classified · 19
• T50 Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances · 19
• T45 Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified · 15
• T38 Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified · 13
• T40 Poisoning by, adverse effect of and underdosing of narcotics and psychodysleptics [hallucinogens] · 13
• T36 Poisoning by, adverse effect of and underdosing of systemic antibiotics · 11
• T44 Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system · 11
• T46 Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system · 11
• T47 Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system · 10
• T48 Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system · 10
• T49 Poisoning by, adverse effect of and underdosing of topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinorlaryngological and dental drugs · 10
• T39 Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics · 9
• T42 Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs · 9
• T37 Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics · 8
• T41 Poisoning by, adverse effect of and underdosing of anesthetics and therapeutic gases · 7

ICD-10-CM Codes in This Category (first 100 of 175)

• T36.0X5A — Adverse effect of penicillins, initial encounter
• T36.1X5A — Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
• T36.2X5A — Adverse effect of chloramphenicol group, initial encounter
• T36.3X5A — Adverse effect of macrolides, initial encounter
• T36.4X5A — Adverse effect of tetracyclines, initial encounter
• T36.5X5A — Adverse effect of aminoglycosides, initial encounter
• T36.6X5A — Adverse effect of rifampicins, initial encounter
• T36.7X5A — Adverse effect of antifungal antibiotics, systemically used, initial encounter
• T36.8X5A — Adverse effect of other systemic antibiotics, initial encounter
• T36.95XA — Adverse effect of unspecified systemic antibiotic, initial encounter
• T36.AX5A — Adverse effect of fluoroquinolone antibiotics, initial encounter
• T37.0X5A — Adverse effect of sulfonamides, initial encounter
• T37.1X5A — Adverse effect of antimycobacterial drugs, initial encounter
• T37.2X5A — Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
• T37.3X5A — Adverse effect of other antiprotozoal drugs, initial encounter
• T37.4X5A — Adverse effect of anthelminthics, initial encounter
• T37.5X5A — Adverse effect of antiviral drugs, initial encounter
• T37.8X5A — Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
• T37.95XA — Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
• T38.0X5A — Adverse effect of glucocorticoids and synthetic analogues, initial encounter
• T38.1X5A — Adverse effect of thyroid hormones and substitutes, initial encounter
• T38.2X5A — Adverse effect of antithyroid drugs, initial encounter
• T38.3X5A — Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
• T38.4X5A — Adverse effect of oral contraceptives, initial encounter
• T38.5X5A — Adverse effect of other estrogens and progestogens, initial encounter
• T38.6X5A — Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
• T38.7X5A — Adverse effect of androgens and anabolic congeners, initial encounter
• T38.805A — Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
• T38.815A — Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
• T38.895A — Adverse effect of other hormones and synthetic substitutes, initial encounter
• T38.905A — Adverse effect of unspecified hormone antagonists, initial encounter
• T38.995A — Adverse effect of other hormone antagonists, initial encounter
• T39.015A — Adverse effect of aspirin, initial encounter
• T39.095A — Adverse effect of salicylates, initial encounter
• T39.1X5A — Adverse effect of 4-Aminophenol derivatives, initial encounter
• T39.2X5A — Adverse effect of pyrazolone derivatives, initial encounter
• T39.315A — Adverse effect of propionic acid derivatives, initial encounter
• T39.395A — Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
• T39.4X5A — Adverse effect of antirheumatics, not elsewhere classified, initial encounter
• T39.8X5A — Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
• T39.95XA — Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
• T40.0X5A — Adverse effect of opium, initial encounter
• T40.2X5A — Adverse effect of other opioids, initial encounter
• T40.3X5A — Adverse effect of methadone, initial encounter
• T40.415A — Adverse effect of fentanyl or fentanyl analogs, initial encounter
• T40.425A — Adverse effect of tramadol, initial encounter
• T40.495A — Adverse effect of other synthetic narcotics, initial encounter
• T40.5X5A — Adverse effect of cocaine, initial encounter
• T40.605A — Adverse effect of unspecified narcotics, initial encounter
• T40.695A — Adverse effect of other narcotics, initial encounter
• T40.715A — Adverse effect of cannabis, initial encounter
• T40.725A — Adverse effect of synthetic cannabinoids, initial encounter
• T40.905A — Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
• T40.995A — Adverse effect of other psychodysleptics [hallucinogens], initial encounter
• T41.0X5A — Adverse effect of inhaled anesthetics, initial encounter
• T41.1X5A — Adverse effect of intravenous anesthetics, initial encounter
• T41.205A — Adverse effect of unspecified general anesthetics, initial encounter
• T41.295A — Adverse effect of other general anesthetics, initial encounter
• T41.3X5A — Adverse effect of local anesthetics, initial encounter
• T41.45XA — Adverse effect of unspecified anesthetic, initial encounter
• T41.5X5A — Adverse effect of therapeutic gases, initial encounter
• T42.0X5A — Adverse effect of hydantoin derivatives, initial encounter
• T42.1X5A — Adverse effect of iminostilbenes, initial encounter
• T42.2X5A — Adverse effect of succinimides and oxazolidinediones, initial encounter
• T42.3X5A — Adverse effect of barbiturates, initial encounter
• T42.4X5A — Adverse effect of benzodiazepines, initial encounter
• T42.5X5A — Adverse effect of mixed antiepileptics, initial encounter
• T42.6X5A — Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
• T42.75XA — Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
• T42.8X5A — Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
• T43.015A — Adverse effect of tricyclic antidepressants, initial encounter
• T43.025A — Adverse effect of tetracyclic antidepressants, initial encounter
• T43.1X5A — Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
• T43.205A — Adverse effect of unspecified antidepressants, initial encounter
• T43.215A — Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
• T43.225A — Adverse effect of selective serotonin reuptake inhibitors, initial encounter
• T43.295A — Adverse effect of other antidepressants, initial encounter
• T43.3X5A — Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
• T43.4X5A — Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
• T43.505A — Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
• T43.595A — Adverse effect of other antipsychotics and neuroleptics, initial encounter
• T43.605A — Adverse effect of unspecified psychostimulants, initial encounter
• T43.615A — Adverse effect of caffeine, initial encounter
• T43.625A — Adverse effect of amphetamines, initial encounter
• T43.635A — Adverse effect of methylphenidate, initial encounter
• T43.655A — Adverse effect of methamphetamines, initial encounter
• T43.695A — Adverse effect of other psychostimulants, initial encounter
• T43.8X5A — Adverse effect of other psychotropic drugs, initial encounter
• T43.95XA — Adverse effect of unspecified psychotropic drug, initial encounter
• T44.0X5A — Adverse effect of anticholinesterase agents, initial encounter
• T44.1X5A — Adverse effect of other parasympathomimetics [cholinergics], initial encounter
• T44.2X5A — Adverse effect of ganglionic blocking drugs, initial encounter
• T44.3X5A — Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
• T44.4X5A — Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
• T44.5X5A — Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
• T44.6X5A — Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
• T44.7X5A — Adverse effect of beta-adrenoreceptor antagonists, initial encounter
• T44.8X5A — Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
• T44.905A — Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
• T44.995A — Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter

The remaining 75 codes are reachable through the code families above.